[Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
Lehnen
M
M
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen.
Goos
M
M
Dissemond
J
J
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000209:etiology; D003879:Dermatologic Agents / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000737:chemistry / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept